The Whole Genome Sequencing Project initiated by The Hospital for Sick Children of Toronto intends to enroll patients between 1 to 18 years of age with congenital heart disease to test genome sequencing methods for personalized diagnoses and treatments. Twenty-five patients were randomly selected to be observed for their consent rate to the project based on factors of age, gender, ethnicity, presence of heart diseases in the patient's family, and the type of congenital heart disease represented. Our studies found that females and ethnicities not of European descent, considered to be part of minority groups, were generally under-represented and had lower consent rates. There were no significant correlations between consent rates and familial history of heart disease, type of heart disease and age groups. These findings can aid in future studies conducted by the SickKids Hospital by indicating which patients may have higher consent rates and by raising inclusivity of minority groups to alleviate bias in medical studies. 
Introduction
What is Congenital Heart Disease?
Congenital heart disease is defined as genetic inheritance of one or more genotypic heart disease alleles inherited through one or both parents (Andelfinger, 2014) , detrimentally affecting children around the world. The rates of such disorders have increasingly caught the attention of clinicians, prompting interest in improving predictions of an offspring inheriting the disease.
If successful, the understanding and reduction of pediatric congenital heart diseases could not only allow for the healthcare system to better address the needs of patients and their families, but also for the earlier commencement of treatments, thus reducing the chance of passing on the allele to the next newborn (Hannah-Shmouni, 2015).
One testing method that is widely recognized for identifying genetic variants potentially implicated in congenital heart disease, is Whole Genome Sequencing (WGS).
Whole Genome Sequencing
Over the last decade, there have been great advancements in genomic technologies, including WGS. This technology has enabled practitioners to identify potential genetic variants implicated in various genetic conditions, which has allowed for a better understanding of genetic makeup of the parent and offspring (Bowdin et. al, 2015) .
By identifying hidden genome markers and other underlying causes of the patient's genetic makeup, the tool has allowed for the typical user to better acknowledge the contributing causes for present disorders, as well as earlier preparation and the prevention of possible diseases suggested by the readings from the procedure (Blue et. al, 2014) . Recently, the cost of WGS has drastically decreased and the use of this tool in clinics has increased (van El et. al, n.d.).
Although the clinical utility of this tool has advantages, it is also accompanied by complications. For example, it is vital to give the family an appropriate amount of time to make a decision on whether or not they will give consent, should also be informed of secondary information that does not relate to the topic of congenital heart diseases but provides insight into other possible genetic disorders (Bowdin et. al, 2015) . This is in addition to the discussion on the types of alleles that patients wish to be disclosed and other genetic information that are used only by the clinician(s) for the purpose of WGS study.
These decisions are approached through counseling with one or more healthcare professionals responsible for addressing advantages and risks possible to the technology.
Our Aim
The goal of this study is to analyze and understand the reasons why a cohort of patients and/or their family will or will not decline the offer to participate in this project.
Randomly chosen families and patients and their primary information are studied to determine if there is a pattern amongst those who have similar backgrounds. By performing this investigation, we may be able to understand how one's medical background may correspond to their willingness to accept WGS, improve the techniques and approaches for patients who are less willing, and ultimately decrease bias and increase diversity in the study. 
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Covariates
The data from 25 patients was taken, and all personal information including the participants name and contact information was removed. Data is shown for all patients and families approached including the gender (male, female, and unidentified), and ethnicity (European, Asian, African, Hispanic, and patients with two or more ethnicities). There was a total of seven types of congenital heart diseases represented in the approached patients:
Pulmonary Stenosis, Atrial Septal Defect,
Tetralogy of Fallot, Hypoplastic Left Heart
Syndrome, Heterotaxy, Dilated Cardiomyopathy, and Transposition of Great Arteries. Finally, the data included whether consent was given by the individuals to participate in the procedure.
Statistical Analysis
The data were graphed, and characteristics Since a large portion of the study's participants were of European ancestry, separate calculations were conducted on this subset of the sample.
They are compared to the same categories created for all 25 patients (gender, age group, type of congenital heart disease and previous familial history) to compare the predominant ethnic group to other minorities of this study. The African ancestry had a ratio of 0:1 given consent to total number of patients. The Asian ancestry had a ratio of 2:3 given consent.
The European ancestry has a ratio of 13:18.
The Hispanic ancestry had a ratio of 0:1.
The subgroup of patients with two or more ethnicities had a ratio of 1:2. We also analyzed the relationship between familial history of congenital heart conditions and consent (Figure 2) . In this category, 16 of the 25 approached patients had a familial history of congenital heart disease(s), and 69.75% (11) of those patients gave consent to the SickKids Genome project. Two-thirds (6) of the patients that did not have a familial record of congenital heart disease(s) (9) also provided consent to the study. A Chi-squared test found no statistical significance between the presence of familial congenital heart disease and providing consent (p= 0.914641).
Of the 25 patients, 12 were male, 12 were female, There were a total of 9 male patients and 8 female patients, with 77.78% (7) (Mucsi et. al, 2017 ).
This may also be due to the European ancestry dominating 54% of approached sample size.
The research on the rates of participations However, eight of the twelve patients were female; the gender considered to be a part of the minority in medical studies and is expected to have a lower consent rate than a group with more males.
Further analysis showed that the remaining four diseases, with higher consent rates did match consent patterns found in previous research. 
